(Taken from Expert Analysis- ACC) This secondary analysis from the EMPEROR-Reduced trial shows that use of empagliflozin reduces the risk of CV death or HF…
View More Beyond Diabetes: The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction
